Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 9/20 | 0.61 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.41 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170934 | 0.92 | ADA (0.66) | ADAHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL6134350 | 0.89 | ADA (0.61) | ADACFDF11TPSB2 | |
| SCHEMBL6133341 | 0.89 | ADA (0.65) | ADA | |
| SCHEMBL6133406 | 0.89 | ADA (0.60) | ADAABCB1 | |
| SCHEMBL6134131 | 0.87 | ADA (0.62) | ADASLC1A5 | |
| SCHEMBL6133435 | 0.87 | ADA (0.62) | ADACFDF11TPSB2 | |
| Hydrochloric Acid SCHEMBL6133491 | 0.86 | ADA (0.59) | ADA | |
| SCHEMBL6134085 | 0.86 | ADA (0.64) | ADA | |
| Hydrochloric Acid SCHEMBL6134529 | 0.86 | ADA (0.59) | ADASLC1A5ABCB1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL6133510 | 0.85 | ADA (0.60) | ADAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | claimed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | claimed |
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ADA 1/4885CFD 4361/4885F11 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.